Alset Inc. Annual Report: A Simple Breakdown

I’ve put together this guide to help you understand how Alset Inc. performed this year. My goal is to explain their complex financial filings in plain English, cutting through the Wall Street jargon.

1. What does this company do?

Alset Inc. acts as a global holding company—essentially a professional deal-maker. They operate through three main areas:

• Real Estate: They buy land and homes, focusing on their "Alset EHome" model. These properties feature smart-home technology and solar energy.
• Digital Transformation: Through subsidiaries, they provide IT services, AI software development, and digital asset consulting.
• Biohealth: They invest in and distribute health products, such as supplements and wellness technology.

Their strategy involves buying majority stakes in companies, managing them, and eventually rotating assets between their U.S. and international holdings.

2. Financial Performance & Health

This was a difficult year for Alset. Revenue dropped from $21.1 million in 2024 to $4.5 million in 2025—a decline of nearly 79%. Losses also grew significantly. The company reported a $49.4 million loss in 2025, compared to a $4.2 million loss the year before. This resulted from falling real estate sales and writing down the value of their assets.

The company reported a "material weakness" in its internal controls, noting a lack of sufficient accounting staff to track finances properly. This creates a risk that financial statements could be inaccurate. They are currently using limited cash reserves to hire consultants to address these reporting issues.

3. Major Wins and Challenges

• The Win: They are modernizing their portfolio of over 100 homes in Texas and Maryland with solar and smart-tech. They are also expanding their tech division to offer AI services, aiming to diversify their software revenue.
• The Challenge: The company frequently closes or merges subsidiaries, which creates a "moving target" for investors. Selling off older assets has left the company with a fragmented balance sheet, making it difficult to track consistent growth year-over-year.

4. Key Risks

• Regulatory Rules: Alset must avoid being classified as an "investment company." If they fail to follow these complex rules, they could face severe operational restrictions or be forced to sell assets.
• International Hurdles: Much of the leadership and assets are based in Asia. This makes it difficult for U.S. investors to hold directors accountable. Additionally, currency swings—specifically regarding $28 million in intercompany loans—continue to impact profits.
• "Insider" Deals: Many major transactions involve the CEO, Chan Heng Fai. When a company frequently trades assets with its own leadership, it is difficult to verify if the transaction prices are fair.
• Operational Hazards: Real estate values can drop, biohealth products may fail to gain regulatory approval, and they face stiff competition in the AI sector.
• Public Company Costs: The company is spending significant capital to fix accounting controls. If they fail to maintain their stock price or resolve these internal issues, they risk being delisted from the Nasdaq.

5. Future Outlook

Alset faces an uphill battle. With an 80% drop in revenue, mounting losses, and ongoing accounting struggles, this remains a high-risk, speculative investment. Their cash position is low, and they rely heavily on "EHome" sales to fund operations.

Investor Takeaway: Before considering an investment, look for signs of consistent profit, a stabilization of their internal accounting controls, and a clearer, more transparent strategy regarding their subsidiary management. Until these issues are resolved, the company remains in a period of significant transition.